← Back

Standard Biotools Inc

Standard BioTools Inc. develops, manufactures, and sells instrumentation, consumables, and services for scientists and biomedical researchers developing therapeutics. It operates through Proteomics and Genomics segments, offering instruments, consumables, and assays for clinical and diagnostic uses. Its platforms include SomaScan, CyTOF, Hyperion, and the Biomark X9 system. The company sells for research use only to academic institutions, research centers, and biopharmaceutical and biotechnology companies. It was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Incorporated in 1999, it is headquartered in Boston, Massachusetts.

Price · split & dividend adjusted
News & notes moving LAB
United States
LAB▼

Standard BioTools posts $20.1 million in Q2 revenue, adjusted EBITDA loss narrows 84%

Standard BioTools reported second-quarter 2026 revenue of $20.1 million, a 7.6% decline from the prior year, while its adjusted EBITDA loss improved 84% to $2.5 million. The company said its merger with Treeline Biosciences is progressing toward a stockholder vote and is expected to close before year-end 2026. Operating expenses fell 1% to $35.9 million, though the net loss from continuing operations widened to $21.5 million, partly due to one-time transaction costs. Standard BioTools also withdrew its full-year 2026 revenue outlook because of the pending merger.
LAB ▼
LAB · Capital · Negative Q2 revenue declined 7.6% and net loss widened due to transaction costs, though EBITDA loss narrowed
Treeline Biosciences · Capital · Positive Merger with Standard BioTools progressing toward stockholder vote and expected to close before year-end
Read original ↗
GlobeNewswire·60dRead more →
LAB▲

Standard BioTools files registration statement for all-stock merger with Treeline Biosciences

Standard BioTools has filed a registration statement with the SEC for its all-stock merger with Treeline Biosciences, a clinical-stage biopharma company. The combined company is expected to have over $900 million in pro-forma cash at closing, which is anticipated in the second half of 2026, and will operate as Treeline Biosciences Holdings under the ticker TRLN. The filing highlights Treeline's pipeline, including headline Phase 1 monotherapy data for TLN-121 in relapsed or refractory lymphomas showing an 84% overall response rate and a 32% complete response rate with no dose-limiting toxicities. Interim data readouts for TLN-121 and TLN-372 are planned for 2027. Treeline also announced that Sue Desmond-Hellmann, former CEO of the Bill & Melinda Gates Foundation, has joined its Board of Directors.
LAB ▲
LAB · Capital · Positive Standard BioTools is merging with Treeline Biosciences, creating a combined entity with over $900M cash and a promising pipeline, which is positive for Standard BioTools shareholders.
Treeline Biosciences · Capital · Positive Treeline Biosciences is the acquirer in an all-stock merger, gaining public listing and access to capital markets, with strong Phase 1 data for TLN-121.
Read original ↗
GlobeNewswire·77dRead more →
LAB

Brodsky & Smith investigates boards of AstroNova, Open Lending, Huntsman, and Standard BioTools over merger deals

Brodsky & Smith is investigating potential fiduciary duty breaches by the boards of four companies in connection with their announced mergers. AstroNova is being acquired by Arcline Investment Management for $29.00 per share in an all-cash deal valued at approximately $272 million. Open Lending is being acquired by ANV Group Holdings for $3.15 per share. Huntsman is being acquired by Olin Corporation, with Huntsman shareholders receiving 0.5476 Olin shares for each Huntsman share, resulting in Huntsman shareholders owning about 45.5% of the combined company. Standard BioTools is being acquired by Treeline Biosciences, with pre-merger Standard BioTools stockholders expected to own approximately 16% of the combined company. The investigations focus on whether the boards failed to conduct a fair process and whether the deal consideration provides fair value to shareholders.
ALOT HUN LAB LPRO OLN
ALOT · Capital · Neutral Investigation into board's fiduciary duties regarding $29/share acquisition deal; outcome uncertain.
HUN · Capital · Neutral Investigation into board's fiduciary duties regarding Olin merger; deal consideration may be unfair.
LAB · Capital · Neutral Investigation into board's fiduciary duties regarding Treeline Biosciences merger; shareholders get 16% of combined company.
LPRO · Capital · Neutral Investigation into board's fiduciary duties regarding ANV Group Holdings acquisition at $3.15/share.
OLN · Capital · Neutral Olin is the acquirer in Huntsman merger; investigation may affect deal terms or reputation.
Read original ↗
GlobeNewswire·107dRead more →
© 2026 MarketDXAsset